Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 298-309

  O'Neill, A J ^a   Huovinen, T ^a   Fishwick, C W G ^a   Chopra, I ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENOTYPE; IN VITRO STUDY; MOLECULAR GENETICS; MOLECULAR MODEL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MODELS, MOLECULAR; MUTATION; PREVALENCE; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 29944432454     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.298-309.2006     Document Type: Article

References (44)

1. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493.
2. Artsimovitch, I., C. Chu, A. S. Lynch, and R. Landick. 2003. A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science 302:650-654.
3. Aubry-Damon, H., C. J. Soussy, and P. Courvalin. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590-2594.
4. Bateman, B. T., N. P. Donegan, T. M. Jarry, M. Palma, and A. L. Cheung. 2001. Evaluation of a tetracycline-inducible promoter in Staphylococcus aureus in vitro and in vivo and its application in demonstrating the role of sigB in microcolony formation. Infect. Immun. 69:7851-7857.
5. Billington, O. J., T. D. McHugh, and S. H. Gillespie. 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:1866-1869.
6. Bottger, E. C., B. Springer, M. Pletschette, and P. Sander. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 4:1343-1344.
7. British Society for Antimicrobial Chemotherapy. 1991. A guide to sensitivity testing; report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 27(Suppl. D):1-50.
8. Campbell, E. A., N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, and S. A. Darst. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
9. Cohan, F. M., E. C. King, and P. Zawadzki. 1994. Amelioration of the deleterious pleiotropic effects of an adaptive mutation in Bacillus subtilis. Evolution 48:81-95.
10. Darst, S. A. 2004. New inhibitors targeting bacterial RNA polymerase. Trends Biochem. Sci. 29:159-160.
11. Doundoulakis, T., A. X. Xiang, R. Lira, K. A. Agrios, S. E. Webber, W. Sisson, R. M. Aust, A. M. Shah, R. E. Showalter, J. R. Appleman, and K. B. Simonsen. 2004. Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 14:5667-5672.
12. Fairweather, N., S. Kennedy, T. J. Foster, M. Kehoe, and G. Dougan. 1983. Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect. Immun. 41:1112-1117.
13. Garibyan, L., T. Huang, M. Kim, E. Wolff, A. Nguyen, T. Nguyen, A. Diep, K. Hu, A. Iverson, H. Yang, and J. H. Miller. 2003. Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. DNA Repair (Amsterdam) 2:593-608.
14. Guex, N., and M. C. Peitsch. 1997. SWISS-MODEL and the swiss-Pdb viewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723.
15. Hansson, S., R. Singh, A. T. Gudkov, A. Liljas, and D. T. Logan. 2005. Structural insights into fusidic acid resistance and sensitivity in EF-G. J. Mol. Biol. 348:939-949.
16. Herrera, L., S. Jimenez, A. Valverde, M. A. Garcia-Aranda, and J. A. Saez-Nieto. 2003. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int. J. Antimicrob. Agents 21:403-408.
17. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
18. Hood, J., B. Cosgrove, E. Curran, M. Lockhart, B. Thakker, and C. Gemmell. 2000. Vancomycin-intermediate resistant Staphylococcus aureus in Scotland. Abstr., 4th Decennial Int. Conf. Nosocomial Healthcare-Associated Infect.
19. Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2004. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J. Antimicrob. Chemother. 53:102-104.
20. Hurdle, J. G., A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra. 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob. Agents Chemother. 48:4366-4376.
21. Jin, D. J., and C. A. Gross. 1988. Mapping and sequencing of mutations in the Escherichia coli rpob gene that lead to rifampicin resistance. J. Mol. Biol. 202:45-58.
22. Jin, D. J., W. A. Walter, and C. A. Gross. 1988. Characterization of the termination phenotypes of rifampicin-resistant mutants. J. Mol. Biol. 202:245-253.
23. Korzheva, N., A. Mustaev, M. Kozlov, A. Malhotra, V. Nikiforov, A. Goldfarb, and S. A. Darst. 2000. A structural model of transcription elongation. Science 289:619-625.
24. Kumari, D. N. P., V. Keer, P. M. Hawkey, P. Parnell, N. Joseph, J. F. Richardson, and B. Cookson. 1997. Comparison and application of ribosome spacer DNA amplicon polymorphisms and pulsed-field gel electrophoresis for differentiation of methicillin-resistant Staphylococcus aureus strains. J. Clin. Microbiol. 35:881-885.
25. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.
26. Lin, W. S., T. Cunneen, and C. Y. Lee. 1994. Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus. J. Bacteriol. 176:7005-7016.
27. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155:360-369.
28. Matsiota-Bernard, P., G. Vrioni, and E. Marinis. 1998. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J. Clin. Microbiol. 36:20-23.
29. Mohamadi, F., N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W. C. Still. 1990. Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11:440-467.
30. Nilsson, A. I., O. G. Berg, O. Aspevall, G. Kahlmeter, and D. I. Andersson. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858.
31. Novick, R. 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33:155-166.
32. O'Neill, A., B. Oliva, C. Storey, A. Hoyle, C. Fishwick, and I. Chopra. 2000. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 44:3163-3166.
33. O'Neill, A. J., and I. Chopra. 2004. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Investig. Drugs 13:1045-1063.
34. Opalka, N., M. Chlenov, P. Chacon, W. J. Rice, W. Wriggers, and S. A. Darst. 2003. Structure and function of the transcription elongation factor GreB bound to bacterial RNA polymerase. Cell 114:335-345.
35. Parenti, F., and G. Lancini. 1997. Rifamycins, p. 453-459. In F. O'Grady, H. P. Lambert, R. G. Finch, and D. Greenwood (ed.), Antibiotic and chemotherapy, 7th ed. Churchill Livingstone, New York, N.Y.
36. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of anti-microbial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29.
37. Reynolds, M. G. 2000. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156:1471-1481.
38. Russell, A. D., and I. Chopra. 1996. Understanding antibacterial action and resistance, 2nd ed. Ellis Horwood, Hertfordshire, United Kingdom.
39. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
40. Sarubbi, E., F. Monti, E. Corti, A. Miele, and E. Selva. 2004. Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. Eur. J. Biochem. 271:3146-3154.
41. Schenk, S., and R. A. Laddaga. 1992. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 73:133-138.
42. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, W. R. Jarvis, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
43. Wichelhaus, T. A., B. Boddinghaus, S. Besier, V. Schafer, V. Brade, and A. Ludwig. 2002. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:3381-3385.
44. Wichelhaus, T. A., V. Schafer, V. Brade, and B. Boddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816.